Mount Yale Investment Advisors LLC Sells 3,838 Shares of STERIS plc (NYSE:STE)

Mount Yale Investment Advisors LLC trimmed its holdings in STERIS plc (NYSE:STE) by 35.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,936 shares of the medical equipment provider’s stock after selling 3,838 shares during the quarter. Mount Yale Investment Advisors LLC’s holdings in STERIS were worth $1,682,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. Central Pacific Bank Trust Division acquired a new position in STERIS during the 3rd quarter valued at $28,000. J.Safra Asset Management Corp raised its position in shares of STERIS by 77.9% during the first quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 53 shares during the last quarter. Quent Capital LLC lifted its stake in shares of STERIS by 112.7% in the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 71 shares during the period. Headlands Technologies LLC acquired a new stake in STERIS during the first quarter worth about $36,000. Finally, Versant Capital Management Inc increased its stake in STERIS by 2,262.5% during the second quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after acquiring an additional 181 shares during the period. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Stock Down 1.4 %

Shares of NYSE STE opened at $224.12 on Friday. The business has a fifty day moving average of $234.76 and a two-hundred day moving average of $226.26. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.49 and a current ratio of 2.33. STERIS plc has a 52-week low of $195.47 and a 52-week high of $248.24. The stock has a market cap of $22.10 billion, a PE ratio of 55.61 and a beta of 0.84.

STERIS (NYSE:STE) last released its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $1.98 by $0.16. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. STERIS had a net margin of 7.36% and a return on equity of 13.85%. The company’s revenue for the quarter was down .4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.00 earnings per share. As a group, equities research analysts expect that STERIS plc will post 9.06 earnings per share for the current fiscal year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 20th. Shareholders of record on Thursday, September 5th were given a $0.57 dividend. This is an increase from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date was Thursday, September 5th. This represents a $2.28 annualized dividend and a yield of 1.02%. STERIS’s payout ratio is presently 56.58%.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research report on Wednesday, August 7th. KeyCorp lifted their price target on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Piper Sandler upgraded shares of STERIS from a “neutral” rating to an “overweight” rating and increased their price objective for the company from $230.00 to $260.00 in a research note on Thursday. StockNews.com upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Stephens reissued an “overweight” rating and issued a $260.00 target price on shares of STERIS in a research note on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, STERIS presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.00.

Insiders Place Their Bets

In other news, Director Christopher S. Holland sold 473 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares in the company, valued at approximately $139,493.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Christopher S. Holland sold 473 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total transaction of $113,368.64. Following the sale, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael J. Tokich sold 23,332 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the completion of the transaction, the chief financial officer now owns 42,930 shares of the company’s stock, valued at $10,603,710. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.14% of the company’s stock.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.